[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postmenopausal-osteoporosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postmenopausal-osteoporosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,80,113,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645032","can-serum-lumican-level-identify-a-hidden-fragility-phenotype-beyond-bone-mineral-density-in-postmenopausal-women-100645032",false,"NCT07677072","Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?","LUMINOS","Inclusion Criteria:\n\nInclusion Criteria:\n\n* Female sex\n* Age 45 years or older\n* Postmenopausal status\n* Attendance at the Physical Medicine and Rehabilitation outpatient clinic\n* Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Premenopausal women\n* Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders)\n* Active infection or acute inflammatory disease\n* Major surgery within the previous 6 months\n* Neurological or muscular disorders that may significantly affect muscle function\n* Inability to comply with study procedures and assessments\n* Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents\n* Refusal or inability to provide written informed consent","FEMALE","45 Years",{"count":19,"type":20},98,"ESTIMATED","OBSERVATIONAL","Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.",[24,25,26,27],"Osteoporosis","Postmenopausal Osteoporosis","Frailty","Fragility Fractures",[29,24,30,31],"Lumican","Fragility","FRAX","RECRUITING","2026-06-24",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2026-05-15",{"date":40,"type":20},"2026-12-01",{"name":42,"class":43},"Kanuni Sultan Suleyman Training and Research Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":44},"100624211","phase-4-the-comparison-of-ibandronate-and-zoledronic-acid-after-denosumab-discontinuation-100624211","NCT07406685","The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation","The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation: A Randomized Non-inferiority Trial","Inclusion Criteria:\n\n1. Postmenopausal women aged 50 to 85 years.\n2. BMD T-score ≤ -1.5 and \\> -3.0 at the lumbar spine or total hip.\n3. Regular treatment with denosumab administered every 6 months for at least 1 year and less than 3 years (3 to 5 doses).\n4. Physically and mentally capable of understanding and complying with the study protocol and follow-up.\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. History of fragility or osteoporotic fracture within the past 12 months.\n2. Current or prior treatment within the past 12 months with osteoporosis medications other than denosumab, including Romosozumab, Teriparatide, Alendronate, Ibandronate, Zoledronic acid, Risedronate and Raloxifene.\n3. Allergy to bisphosphonates.\n4. Secondary osteoporosis.\n5. Metabolic bone diseases.\n6. Any autoimmune disease.\n7. Requirement for long-term use of medications known to affect bone metabolism (e.g., systemic glucocorticoids or hormone therapy).\n8. Primary or metastatic bone tumors.\n9. Cancer patients, except for in situ carcinoma and non-melanoma skin cancer, unless fully treated and in remission for five years.\n10. Hypocalcemia.\n11. Vitamin D deficiency (serum 25-hydroxyvitamin D \\\u003C 25 ng\u002FmL).\n12. Renal disease (eGFR \\\u003C 35 mL\u002Fmin\u002F1.73 m²) or dialysis patients.\n13. Planned dental procedures (e.g., extractions, implants) within the next year.\n14. Smoking more than one pack per day (except for those who have quit for over ten years).","50 Years","85 Years",{"count":55,"type":20},52,"INTERVENTIONAL",[58],"PHASE4","This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are expected to provide foundational evidence to inform the design of future studies assessing sequential therapies following longer-term denosumab treatment.",[25,61,62,24],"Postmenopausal Osteopenia","Primary Osteoporosis",[64,24,65,66,67,68,69],"Postmenopausal","Osteopenia","Denosumab","Ibandronate","Zoledronic acid","Discontinuation","NOT_YET_RECRUITING","2026-02-09",{"date":73,"type":36},"2026-02-12",{"date":75,"type":20},"2026-03-17",{"date":77,"type":20},"2030-09-17",{"name":79,"class":43},"National Taiwan University Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":56,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100621045","phase-1-blackcurrants-modify-gut-microbiota-and-reduce-osteoporosis-risk-in-postmenopausal-females-100621045","NCT07365514","Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females","Blackcurrants Mitigate Postmenopausal Bone Loss Through Gut Microbiota-Bone Axis: A Randomized Clinical Trial Coupled With a Multi-Omics Approach to Inform Precision Nutrition","Inclusion Criteria:\n\n* postmenopausal (defined as no more than 10 years since final menstrual cycle) females aged 45-70 years\n* not on hormone replacement therapy for at least one year before initiation of the study\n* maintaining normal exercise level (\\\u003C 7 hours\u002Fweek) and willing to avoid exercise for 24 hours prior to blood and stool sampling\n* willing to ingest a dietary blackcurrant supplement or placebo (up to 1,176 mg\u002Fday, three 392mg capsules)\n* willing to avoid other dietary supplements for the duration of the study\n* willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli\n* willing to have three blood draws, three stool collections, and three bone scans\n\nExclusion Criteria:\n\n* history of cardiovascular disease, osteoporosis, metabolic bone disease, cancer, diabetes mellitus, arthritis, or other chronic inflammatory diseases\n* current smokers\n* taking prescription medications known to alter bone and calcium metabolism\n* taking anabolic agents such as parathyroid hormone or growth hormone, or steroid within 3 months before the start of the study\n* taking medications that alter bleeding (such as antiplatelets or anticoagulants) or those with a bleeding disorder\n* alcohol consumption exceeding 2 drinks\u002Fday (approximately 14g of ethanol per drink) or a total of 12\u002Fweek\n* those with planned surgery during the study period or within 2 weeks of ending the intervention\n* those with sensitivities or allergies to any of the ingredients for the placebo (rice powder)\n* planning a procedure that includes iodine, barium or nuclear medicine isotopes within the study period\n* UConn students and\u002For employees who any key personnel teach or who report to any key personnel\n* study key personnel, partners of key personnel, or dependents\u002Frelatives of any key personnel",true,"70 Years",{"count":90,"type":20},159,[92],"PHASE1","The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.",[25,95,96],"Gut Microbiome","Menopause",[98,99,100,101,102,103],"blackcurrant","gut microbiome","osteoporosis","menopause","females","bone aging","2026-01-25",{"date":106,"type":36},"2026-01-27",{"date":108,"type":20},"2026-02-01",{"date":110,"type":20},"2029-09",{"name":112,"class":43},"University of Connecticut",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":120,"minAge":52,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100618278","age-burden-and-response-to-antiresorptive-therapy-in-osteoporosis-100618278","NCT07329543","AGE Burden and Response to Antiresorptive Therapy in Osteoporosis","Association of Advanced Glycation End-Product Burden With Response to Antiresorptive Therapy and Residual Fracture Risk in Osteoporosis: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Diagnosis of osteoporosis based on dual-energy X-ray absorptiometry (DXA) criteria (T-score ≤ -2.5 at the lumbar spine, total hip, or femoral neck) or presence of a prior fragility fracture\n* Planned initiation of antiresorptive therapy (denosumab or bisphosphonate) as part of routine clinical care\n* Ability to undergo DXA measurements at baseline and during follow-up\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of diabetes mellitus (type 1 or type 2)\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Active malignancy or history of malignancy within the past 5 years\n* Secondary causes of osteoporosis (including hyperparathyroidism, hyperthyroidism, Cushing's syndrome, malabsorption syndromes, or chronic liver disease)\n* Use of medications known to significantly affect bone metabolism other than antiresorptive therapy (e.g., long-term systemic glucocorticoids, anabolic osteoporosis agents)\n* Prior treatment with denosumab or bisphosphonates within the last 12 months\n* Inflammatory rheumatic diseases or chronic inflammatory conditions that may affect bone metabolism\n* Pregnancy or breastfeeding\n* Inability to comply with study procedures or follow-up visits","ALL",{"count":122,"type":20},240,"Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to experience fractures despite treatment.\n\nAdvanced glycation end-products (AGEs) accumulate in the body over time and can negatively affect bone quality by altering collagen structure and increasing inflammation. The role of AGE burden in predicting response to osteoporosis treatment has not been fully established.\n\nThis prospective cohort study aims to evaluate whether baseline AGE burden, measured non-invasively using skin autofluorescence, is associated with treatment response in patients receiving antiresorptive therapy for osteoporosis. Changes in bone mineral density, bone turnover markers, and fracture outcomes will be analyzed in relation to baseline AGE levels. The results of this study may help identify patients at risk for reduced treatment response and residual fracture risk.",[24,25],"2026-01-08",{"date":127,"type":36},"2026-01-09",{"date":129,"type":20},"2026-01-15",{"date":131,"type":20},"2027-04-15",{"name":133,"class":134},"Bursa City Hospital","OTHER_GOV",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":56,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100575043","phase-4-strategies-for-zoledronic-acid-post-denosumab-discontinuation-in-postmenopausal-osteoporosis-100575043","NCT06767150","StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis","SAFEST","Inclusion Criteria:\n\n* Women with post-menopausal osteoporosis\n* And treated with denosumab for at least 2 years and reaching decision of denosumab withdrawal because of achieved therapeutic target defined as no fracture during treatment; no new risk factors; no BMD decrease \\> 0.03 g\u002Fcm² at the spine or hip;\n* And with a history of severe fracture or a femoral or lumbar T-score ≤ -2.5 prior denosumab initiation.\n\nExclusion Criteria:\n\n* Dmab use for bone disease other than post-menopausal osteoporosis.\n* Uncontrolled endocrine diseases. Liver failure.\n* Use of medication affecting bone metabolism during the last year, including bisphosphonates, teriparatide, romosozumab, Selective Estrogen Receptor Modulators, breast cancer hormonotherapy, glucocorticoids over 5 mg\u002Fday.\n* Contra-indication to bisphosphonates according to license recommendation including chronic kidney disease with GFR stage \\> or = G3b. Prior intolerance to zoledronic acid.\n* Subjects unable to give an informed consent or to fill the case report form. Subjects under law protection.\n* Foreseeable poor compliance with the strategy, alcoholism, toxicomania.","18 Years",{"count":144,"type":20},200,[58],"Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.",[25],[149,150,151,152,153,154],"Postmenopausal osteoporosis","strategy","denosumab","zoledronate","rebound","withdrawal","2025-12-23",{"date":157,"type":36},"2025-12-31",{"date":159,"type":36},"2025-10-02",{"date":161,"type":20},"2030-10",{"name":163,"class":43},"University Hospital, Toulouse",17]